Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

Inclusion Criteria:

1. Epithelial ovarian cancer/tubal cancer/peritoneal cancer was diagnosed byhistopathology or hydroexfoliation cytopathology of the chest and abdomen, and wasclassified as stage III-IV according to FIGO（International Federation of Gynecologyand Obstetrics）stage

2. Physical condition Eastern Cooperative Oncology Group PS score: 0-2 points

3. Participants who had not participated in other drug clinical trials within 4 weeksprior to enrollment

4. Written informed consent

5. Expected survival ≥6 months

6. The disease met the criteria for Efficacy Evaluation of solid tumors (RECIST 1.1)

7. Be able to comply with outpatient treatment, laboratory monitoring, and necessaryclinical visits during study participation.

Exclusion Criteria:

1. Patients with low malignant potential ovarian tumors;

2. Other malignant tumors within the previous 5 years, except for cured cervicalcarcinoma in situ and non-melanoma skin cancer;

3. Patients who have previously received chemotherapy or radiotherapy for pelviccavity;

4. Patients with central nervous system metastasis or peripheral neuropathy > grade 1;

5. Patients with severe myelosuppression, severe liver dysfunction (Child's Class III),or renal dysfunction at the time of screening;

6. Severe cardiovascular disease: Grade Ⅱ or above myocardial ischemia or myocardialinfarction, poorly controlled arrhythmias (including QTc interval ≥470 ms);According to NYHA（New York Heart Association） criteria, patients with grade Ⅲ to Ⅳcardiac insufficiency or left ventricular ejection fraction (LVEF) < 55% indicatedby color Doppler ultrasonography;

7. Uncontrolled systemic infection requiring anti-infective treatment;

8. Arteriovenous thrombosis events occurring within 6 months before randomization, suchas cardiovascular and cerebrovascular accidents (including temporary ischemicattack, cerebral hemorrhage, cerebral infarction, myocardial infarction), deep veinthrombosis and pulmonary embolism;

9. Patients who are allergic to the active ingredients or excipients of albuminpaclitaxel and carboplatin for injection;

10. Pregnant or lactating women;

11. Those who were considered unsuitable for inclusion by the researchers.